- Home
- KODK vs YMAB Comparison
KODK vs YMAB Comparison
Compare KODK & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KODK
- YMAB
- Stock Information
- Founded
- KODK 1880
- YMAB 2015
- Country
- KODK United States
- YMAB United States
- Employees
- KODK N/A
- YMAB N/A
- Industry
- KODK Business Services
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- KODK Consumer Discretionary
- YMAB Health Care
- Exchange
- KODK Nasdaq
- YMAB Nasdaq
- Market Cap
- KODK 476.6M
- YMAB 386.7M
- IPO Year
- KODK N/A
- YMAB 2018
- Fundamental
- Price
- KODK $6.03
- YMAB $8.61
- Analyst Decision
- KODK
- YMAB Buy
- Analyst Count
- KODK 0
- YMAB 10
- Target Price
- KODK N/A
- YMAB $13.91
- AVG Volume (30 Days)
- KODK 1.0M
- YMAB 842.3K
- Earning Date
- KODK 11-11-2025
- YMAB 11-07-2025
- Dividend Yield
- KODK N/A
- YMAB N/A
- EPS Growth
- KODK N/A
- YMAB N/A
- EPS
- KODK N/A
- YMAB N/A
- Revenue
- KODK $1,037,000,000.00
- YMAB $85,385,000.00
- Revenue This Year
- KODK N/A
- YMAB N/A
- Revenue Next Year
- KODK N/A
- YMAB $13.97
- P/E Ratio
- KODK N/A
- YMAB N/A
- Revenue Growth
- KODK N/A
- YMAB N/A
- 52 Week Low
- KODK $4.26
- YMAB $3.55
- 52 Week High
- KODK $8.24
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- KODK 50.12
- YMAB 81.21
- Support Level
- KODK $5.73
- YMAB $8.50
- Resistance Level
- KODK $6.22
- YMAB $8.56
- Average True Range (ATR)
- KODK 0.20
- YMAB 0.02
- MACD
- KODK 0.04
- YMAB -0.13
- Stochastic Oscillator
- KODK 58.16
- YMAB 112.50
About KODK Eastman Kodak Company Common New
Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.